Guardant Health Q3 revenue $117.4M (+24% YoY); cuts full-year revenue guidance to $440-450M

Guardant Health, Inc.

2022-Q3 EPS reported -$5.04 revenue$322,647,000

Q3 clinical test volume 32,400 (+42% YoY); biopharma tests 6,750 (+40% YoY).
GAAP net loss per share -$1.58; non-GAAP -$1.18; Adj. EBITDA loss -$112.8M.
Full-year 2022 revenue guidance lowered to $440-450M from $460-470M, citing challenging backdrop.
FDA approved Guardant360 CDx as companion diagnostic for ENHERTU in HER2-mutant NSCLC.
ECLIPSE readout and Shield PMA submission expected in Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Guardant Health, Inc. reported the quarter ended September 30, 2022 results: revenue $117.4 million, net income $162.0 million, EPS $1.58. Guidance lowered.

Period: the quarter ended September 30, 2022
Revenue: $117.4 million
Net income: $162.0 million
EPS: $1.58
Guidance: lowered
Result: reported results

Exact text from the filing

use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021 • Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-22-000091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.